Abstract
The m6A reader YTHDF1 is required for progression of acute myelogenous leukemia and can be targeted with the FDA-approved drug tegaserod to suppress leukemia growth.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have